Comparative Pharmacology
Head-to-head clinical analysis: CIPRO HC versus FOSFOMYCIN TROMETHAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRO HC versus FOSFOMYCIN TROMETHAMINE.
CIPRO HC vs FOSFOMYCIN TROMETHAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription; hydrocortisone suppresses inflammation via glucocorticoid receptor activation.
Fosfomycin inhibits bacterial cell wall synthesis by inactivating the enzyme UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), which catalyzes the first step of peptidoglycan biosynthesis.
Instill 3 drops into the affected ear(s) twice daily (morning and evening) for 7 days.
3 g orally once as a single dose for uncomplicated urinary tract infection.
None Documented
None Documented
Ciprofloxacin: 4-6 hours (prolonged to 6-9 hours in elderly or renal impairment). Hydrocortisone: 1-2 hours.
Terminal elimination half-life is 5.7 hours (range 3-8 hours) in patients with normal renal function; approximately 50 hours in end-stage renal disease (CrCl <10 mL/min).
Ciprofloxacin: ~50-70% excreted renally as unchanged drug, ~15% as metabolites; ~20-30% eliminated via biliary/fecal route. Hydrocortisone: metabolized hepatically, renal excretion of metabolites.
Primarily excreted unchanged in urine via glomerular filtration (approximately 90% of absorbed dose within 24-48 hours); small amount (approximately 10%) excreted in feces via biliary elimination.
Category C
Category A/B
Antibiotic/Corticosteroid Combination (Otic)
Antibiotic